Ophthalmology

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Retrieved on: 
Thursday, March 7, 2024
Cristin, SAN, School, Ophthalmology, Roche, Growth, Public health, MBA, Molecular biology, Postgraduate education, University, Haemophilia, Business, BioMarin Pharmaceutical, Triple accreditation, Patient, Infection, BMRN

SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.

Key Points: 
  • SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer.
  • Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.
  • Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and diagnostics industries.
  • He has worked at BioMarin for more than 18 years, including 11 as chief commercial officer.

SightMD Welcomes Cynthia Zara, OD to its expert team in New York

Retrieved on: 
Monday, March 4, 2024
Diabetes, Ophthalmology, Food Network, Infection, Eye, Floater, Southern College of Optometry, Volunteering, State university system, School, Contact, Macular degeneration, Chalazion, OD, Patient, Glasses, Risk, Glaucoma, Food, Whaling

HAUPPAUGE, N.Y., March 4, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.

Key Points: 
  • SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.
  • HAUPPAUGE, N.Y., March 4, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.
  • Cynthia Zara, OD is a board-certified optometrist providing dilation exams, contact lenses and eyeglasses, dry eye treatments, and more.
  • When asked what she is looking forward to most about joining the SightMD Team, Dr Zara said "I am excited to be joining SightMD in Hamptons Bays and Southampton.

PMB Project Named 2023 HREI Insights™ Award Winner

Retrieved on: 
Monday, March 4, 2024
OB/GYN, SAN, Ophthalmology, Woman, PMB, Winners, Elective surgery, SF, Partner (business rank), Mental, HRE, Gastroenterology, Nursing

SAN DIEGO, March 4, 2024 /PRNewswire/ -- The PMB-developed healthcare project has been named a Winner in Healthcare Real Estate Insights (HREI) magazine's annual, national awards program.

Key Points: 
  • SAN DIEGO, March 4, 2024 /PRNewswire/ -- The PMB-developed healthcare project has been named a Winner in Healthcare Real Estate Insights (HREI) magazine's annual, national awards program.
  • PMB Project Named 2023 HREI Insights Award Winner: Helen Caloggero Women's & Family Center
    "We are very pleased that HREI magazine has once again recognized the excellence of PMB's healthcare real estate projects," says Mark D. Toothacre, Managing Partner and CEO of PMB.
  • PMB has had 13 Finalists, eight of which have now been named Winners in the previous eight years of the awards program.
  • The awards are presented by HREI, the first and only national magazine entirely devoted to covering HRE development, financing and investment.

Cardinal Health annual research report examines milestone year in biosimilars

Retrieved on: 
Thursday, February 29, 2024
Retina, Ophthalmology, Adalimumab, Cardinal Health, MBA, Research, Doctor of Pharmacy, Patient, Generic drug

DUBLIN, Ohio, Feb. 29, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars. The publication highlights legislative developments and new treatments, including adalimumab biosimilars. The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.

Key Points: 
  • DUBLIN, Ohio, Feb. 29, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars.
  • The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.
  • The report examines a year of major developments in biosimilars, offering expert commentary and provider perspectives on a rapidly changing industry landscape.
  • With 2024 expected to be a critical year for retina biosimilars, Cardinal Health surveyed providers in ophthalmology to obtain perspectives that may influence adoption while highlighting continued obstacles to wider use of biosimilars.

Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Retrieved on: 
Sunday, February 25, 2024
Allergy, Ophthalmology, AAAAI, Omalizumab, Upper respiratory tract infection, Dermatology, Allergic rhinitis, Season, Hematology, Rhinitis, Immunology, Patient, Autoimmunity, Clinical trial, PPP, SOC, Asthma, Insurance, American Academy, Pharmaceutical industry

The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.

Key Points: 
  • The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.
  • This Phase II study shows that 100mg LP-003 significantly improved nasal symptoms (TNSS score) of uncontrolled seasonal allergic rhinitis patients despite SoC treatment.
  • We are honored to unveiled the exciting Phase II results of LP-003, the first registrational clinical trial of anti-IgE antibody for AR conducted in China."
  • As Longbio Pharma charts its course forward, the successful Phase II study of LP-003 in allergic rhinitis represents a pivotal milestone in advancing the treatment landscape for allergic diseases.

MEMS in the Global Medical Market: New Report with 2020-2023 Data, CAGR Projections to 2028 and Profiles of Leading Players TE Connectivity, STMicroelectronics, Teledyne Dalsa and Silex Microsystems

Retrieved on: 
Thursday, February 22, 2024
MEMS, Ophthalmology, Regeneration, Drug, DDS, Toxicity, USD, Pressure, Silicon, Intelligence, Permeability, Temperature, Immunology, Cardiology, Honeywell, Growth, Polymer, Teledyne DALSA, ESG, Endocrinology, TE Connectivity, STMicroelectronics, Administration, Glass, Metal, Microelectromechanical systems, Route of administration, Solubility, Proteomics, LOC, Genomics, Diagnosis, Research, Biochemistry

DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 22, 2024 /PRNewswire/ -- The 'Microelectromechanical Systems (MEMS) in Global Medical Markets' report has been added to ResearchAndMarkets.com's offering.
  • Of these, microfluidic and LOC devices account for the largest segment of the MEMS device market.
  • In terms of microfluidic devices, the key potential lies in developing cartridges that are highly sensitive, multichannel and multiplexing systems.
  • Competitive intelligence related to leading companies, their global rankings, recent developments, key financials and segmental revenues, and product portfolios
    Profiles of the leading market players, including TE Connectivity, Honeywell International Inc., STMicroelectronics, Teledyne Dalsa, and Silex Microsystems

Console & Associates, P.C.: American Vision Partners Reports Data Breach Exposing SSNs and Medical Information of 2.3 Million

Retrieved on: 
Wednesday, February 21, 2024
Ophthalmology, Social, Console, Risk, Identity theft, Social Security, Crime, Patient, Lawyer, Civil and political rights, Face, P.C, Birth control

d/b/a/ American Vision Partners ("American Vision Partners'' or "MMRG").

Key Points: 
  • d/b/a/ American Vision Partners ("American Vision Partners'' or "MMRG").
  • However, victims of the breach may not be familiar with the name American Vision Partners because it works with ophthalmology practices in a behind-the-scenes role.
  • Thus, it's possible American Vision Partners has information about patients who were entirely unaware that was the case.
  • American Vision Partners explained that the incident stemmed from a cybersecurity incident that the company first discovered on November 14, 2023.

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on: 
Thursday, February 15, 2024
Oncology, Health, Neurology, Genetics, Pharmaceutical, Cardiology, Biotechnology, Alexion Pharmaceuticals, Ophthalmology, Indiana University, Metabolism, Rock, Growth, Diabetes, MBA, Allergan, Doctor of Philosophy, SMA, Genentech, Roche, University, Therapy, MPH, Medicine, American University, Baylor College of Medicine, Gongshi, Master of Science, Obesity, Research, Spinal muscular atrophy, Amgen, Management

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points: 
  • “We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
  • Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
  • Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
  • “I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.

Advancing Clinical Excellence: 20/20 Onsite Life Sciences Clinic Managers Achieve Prestigious Certified Paraoptometric Status

Retrieved on: 
Wednesday, February 14, 2024
Optical, Health, Clinical Trials, Ophthalmology, Certification, Education, CPO, CONFIG.SYS, AOA, Doctor, Patient, Knowledge, American Optometric Association, Nursing

20/20 Onsite, a leader in innovative mobile clinical vision solutions, proudly announces that all of its Life Sciences clinic managers are now Certified Paraoptometrics (CPOs) after a stringent examination process.

Key Points: 
  • 20/20 Onsite, a leader in innovative mobile clinical vision solutions, proudly announces that all of its Life Sciences clinic managers are now Certified Paraoptometrics (CPOs) after a stringent examination process.
  • The Certified Paraoptometric (CPO) designation is a national certification awarded to individuals who have demonstrated a comprehensive understanding of the concepts and practices utilized in optometric care.
  • Achieving CPO status signifies that 20/20 Onsite’s Life Sciences clinic managers have demonstrated an in-depth understanding of various subject areas within optometry and have committed to upholding the highest standards of care in the eye care industry.
  • “With this deeper scope of practice, our certified clinic managers can further alleviate the barriers to staffing that so often delay or derail ophthalmology assessments on clinical trials.”

SightMD Welcomes J. Kevin Belville, MD to its expert team

Retrieved on: 
Tuesday, February 13, 2024
Ophthalmology, United, MD, Commerce, Diabetic retinopathy, Saint Louis University, United Nations, Macular degeneration, Weill Cornell Medicine, Patient, Laser, UCLA

HAUPPAUGE, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes J. Kevin Belville, MD to its expert team.

Key Points: 
  • SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes J. Kevin Belville, MD to its expert team.
  • HAUPPAUGE, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes J. Kevin Belville, MD to its expert team.
  • Dr. J. Kevin Belville is a board-certified ophthalmologist who completed his residency as Chief Resident at Cornell Medical Center at the New York-Presbyterian Columbia University Hospital in New York City.
  • SightMD is actively seeking ophthalmology professionals who are interested in joining our outstanding team.